SCHEMBL9907342

SCHEMBL9907342

O=C(O)c1ccc2nccc(-c3ccc(Cl)cc3Cl)c2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A2 P31213 3/20 0.49
KDM4C Q9H3R0 1/20 0.47
MAPKAPK2 P49137 1/20 0.46
SRD5A1 P18405 1/20 0.44
DHODH Q02127 1/20 0.43
KDM4E B2RXH2 1/20 0.43
NPC1 O15118 1/20 0.43
CRHBP P24387 1/20 0.43
RAB9A P51151 1/20 0.43
CRHR2 Q13324 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CSNK2A2 P19784 1/20 0.43
CSNK2B P67870 1/20 0.43
MAPT P10636 1/20 0.42
TTR P02766 2/20 0.42
CDH1 P12830 1/20 0.42
APC P25054 1/20 0.42
CTNNB1 P35222 1/20 0.42
TCF7L2 Q9NQB0 1/20 0.42
CHEK2 O96017 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9907362 0.89 MAPKAPK2 (0.49) SRD5A2KDM4CMAPKAPK2SRD5A1KDM4E
SCHEMBL9907352 0.87 KMO (0.51) SRD5A2KDM4CMAPKAPK2SRD5A1CSNK2A2
SCHEMBL9907353 0.87 GRM2 (0.44) KDM4CMAPKAPK2
SCHEMBL9907387 0.86 MAPKAPK2 (0.45) SRD5A2KDM4CMAPKAPK2KDM4ENPC1
SCHEMBL9907372 0.85 MAPKAPK2 (0.48) SRD5A2MAPKAPK2SRD5A1CSNK2A2CSNK2B
SCHEMBL9907338 0.85 HTT (0.47) KDM4CKDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL9907791 0.83 HTR5A (0.53) NR4A2
SCHEMBL9907343 0.80 DOT1L (0.42) KDM4CMAPKAPK2NPC1RAB9ACSNK2A2
SCHEMBL9907363 0.80 DOT1L (0.44) KDM4CMAPKAPK2NPC1RAB9ACSNK2A2
SCHEMBL7689552 0.79 TSHR (0.48) KDM4CMAPKAPK2KDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
EP-2463276-B1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC (JP) 2014-03-12 EP disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed
WO-2011016504-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE アステラス製薬株式会社 (JP) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E SRD5A2 509/4885KDM4C 1366/4885MAPKAPK2 4333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.